Dilution of share value through the exercise of stock acquisition rights
First written in FY2020. 7 of 14 entries say "Materialised", first in FY2023-Q1. Latest entry: FY2026.
MetaReal moved to the "Worse" side of this theme in 2020, 1 year before the typical company in this theme (2021).
The whole theme swung hardest in 2017: 28 of 54 companies on the "Worse" side.
32 other companies' latest entry also says "Worsened".
- FY2026WorsenedAnnual report
「As of the end of February 2026, the number of potential shares attributable to stock acquisition rights was 150,000, equivalent to 1.4% of the total 10,888,060 shares issued.」
Following the lapse of the 14th Stock Acquisition Rights, 150,000 shares equivalent of the 15th Stock Acquisition Rights were newly granted, and the potential for dilution from potential shares was disclosed again. - FY2026-H1MitigatedAnnual report
「The Series 14 stock acquisition rights approved by the Board of Directors on 14 July 2020 lapsed upon expiration of the exercise period.」
The lapse of the 14th Stock Acquisition Rights upon expiration of the exercise period is being reconfirmed. No relevant stock acquisition rights or similar instruments existed at the end of the interim accounting period, and no additional potential dilution from potential shares was disclosed. - FY2025Completion of exercise of stock acquisition rights; Series 14 rights lapsedAnnual report
「For the Series 11 stock acquisition rights, 119,600 shares were exercised, 2,400 shares lapsed, and there is no remaining balance of unexercised rights. The Series 14 stock acquisition rights also lapsed upon expiration of the exercise period.」
During the consolidated fiscal year, the remaining Series 11 stock acquisition rights were exercised or lapsed, leaving no unexercised balance. The Series 14 stock acquisition rights, equivalent to 1,218,800 shares, also lapsed upon expiration of the exercise period. - FY2025-H1MaterialisedAnnual report
「1 March 2024–31 August 2024 (Note) 119,600 10,888,060 9,747 802,289 9,747 743,234 (Note) Increase resulting from the exercise of stock acquisition rights.」
Through the exercise of stock acquisition rights, 119,600 shares were issued during the current interim consolidated accounting period, and the dilution risk materialized as an additional share issuance. Meanwhile, the Series 14 stock acquisition rights are stated to have lapsed upon expiration of the exercise period. - FY2025-Q1MaterialisedAnnual report
「1 March 2024–31 May 2024 (Note) 1,200 10,769,660 97 792,639 97 733,584 (Note) Increase resulting from the exercise of stock acquisition rights.」
Through the exercise of stock acquisition rights, 1,200 shares were issued during the current first quarter, and the dilution risk materialized as an additional share issuance. - FY2024MaterialisedAnnual report
「Common shares 10,688,460 80,000 — 10,768,460」
During the consolidated fiscal year, 80,000 shares were issued through the exercise of stock acquisition rights, and the dilution risk materialized as an additional share issuance. - FY2024-Q3MaterialisedAnnual report
「1 September 2023–30 November 2023 (Note) 6,400 10,768,460 521 792,541 521 733,486 (Note) Increase resulting from the exercise of stock acquisition rights.」
Through the exercise of stock acquisition rights, 6,400 shares were issued during the quarter, increasing total issued shares, capital stock and the capital surplus reserve. The dilution risk has materialized as an additional share issuance. - FY2024-Q2MaterialisedAnnual report
「1 June 2023–31 August 2023 (Note 1) 73,600 10,762,060 5,998 792,020 5,998 732,965 (Note) 1. Increase resulting from the exercise of stock acquisition rights.」
Through the exercise of stock acquisition rights, total issued shares increased by 73,600 during the current second quarter, while capital stock and the capital surplus reserve each increased by ¥5.998 million. The dilution risk has materialized as an additional share issuance. - FY2023-Q2MaterialisedAnnual report
「Change in total issued shares: 400 shares」
Between 1 June and 31 August 2022, total issued shares increased by 400 through the exercise of stock acquisition rights. The dilution risk from exercise has materialized as an additional share issuance. - FY2023-Q1MaterialisedAnnual report
「(Note) Increase due to exercise of stock acquisition rights.」
During the current first quarter, total issued shares increased by 30,400, attributed to the exercise of stock acquisition rights. The dilution risk from exercise of the stock acquisition rights has materialized as an actual share issuance. - FY2021WorsenedAnnual report
「As of the end of April 2021, the number of potential shares from stock acquisition rights was 1,451,600, equivalent to 13.6% of the total 10,657,660 issued shares.」
Potential shares increased to 1,451,600, or 13.6% of total issued shares, from the previously reported 1,218,800. The occurrence of dilution through exercise of the stock acquisition rights is not reported. - FY2021-Q2WorsenedAnnual report
「Stock acquisition rights issued during the current second-quarter accounting period were as follows: number of stock acquisition rights (units), 12,188; class, description and number of shares underlying the stock acquisition rights, common shares, 1,218,800.」
The company issued 12,188 Series 14 stock acquisition rights, establishing potential shares of 1,218,800. Since exercise has not yet been confirmed, dilution itself is not deemed to have occurred. - FY2021-Q1WorsenedAnnual report
「Potential shares from this issuance: 1,218,800 shares (100 shares per stock acquisition right)」
The issuance of 12,188 Series 14 stock acquisition rights through a third-party allotment was approved, indicating the potential for an additional 1,218,800 shares of dilution. Since exercise has not yet been reported, dilution itself is not deemed to have occurred. - FY2020First statedAnnual report
「As of the end of April 2020, the number of potential shares from stock acquisition rights was 323,500, equivalent to 3.1% of the total 10,331,060 issued shares. If these stock acquisition rights are exercised, the value per share could be diluted.」
The company states that potential shares totaled 323,500, or 3.1% of total issued shares, and describes the dilution risk upon exercise of the stock acquisition rights.